Definiens is a provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Its software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, the company helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives.

Employee Rating

Parent CompanyAstraZeneca
HQMünchen, DE
Definiens was founded in 1994 and is headquartered in München, DE

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Definiens

Thomas P. Heydler

Thomas P. Heydler

Chairman & CEO
Markus Schunk

Markus Schunk

Show more

Definiens Office Locations

Definiens has offices in München and Cambridge
München, DE (HQ)
Bernhard-Wicki-Strasse 5
Cambridge, US
125 Cambridgepark Dr #300
Show all (2)

Definiens Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$33.3 m


Definiens is a subsidiary of AstraZeneca

Definiens Online and Social Media Presence

Embed Graph

Definiens News and Updates

Definiens présente des solutions pharmacologiques pour le profilage immuno-oncologique

Son approche de phénomique des tissus accélère le développement d'essais cliniques et le profilage des patients MUNICH, 3 octobre 2018 /PRNewswire/ -- Definiens, société ayant développé l'approche Tissue Phenomics®, a annoncé que le premier forum Definiens Insights se tiendra à son siège...

Digital Pathology Systems Global Market 2018: Key Players – 3Dhistech Ltd, Apollo Enterprise Imaging Corp, Corista LLC, Definiens AG, Philips Healthcare

Wiseguyreports.Com adds “Digital Pathology Systems Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Definiens AG Announces the Appointment of Markus Schunk as Chief Operating Officer

Definiens is an international company with more than 100 employees worldwide with headquarters in Germany and the United States

Definiens Blogs

Why AI-powered Biomarker Analysis is the Future of Cancer Immune Profiling

The development of checkpoint inhibitor therapies is undoubtedly a major advance in cancer treatment. But first, these drugs must undergo extensive clinical research, which requires precision, efficacy, and speed before they reach the doctor’s office. It’s time for a broader approach – a…

Why Using AI in Patient Profiling Enhances Precision Oncology

The introduction of checkpoint inhibitors in clinical oncology has transformed the way we treat cancer patients. Currently, observed sustained clinical responses have given patients new hope. And yet, these treatments don’t provoke the exact immune response in every patient. The big ques…

Harness the Power of Deep Learning for Better TNM Cancer Staging

Artificial Intelligence (AI) has an enormous computational power to process large, complex quantities of data. And yet, to harness this power, seasoned and astute computer scientists must leverage both their knowledge and experience to apply the right techniques for the best results ever…

Applying AI to Digital Pathology for Cancer Research and Clinical Development

Dr. Ralf Huss, Chief Medical Officer at Definiens, explains how the innovative combination of artificial intelligence (AI) and expert knowledge is critical for driving the successful adoption of digital solutions in cancer research. 

How To Cope With An Evolving Immuno-Oncology Field And Changes In Pathology

2018 will be remembered as a decisive year for immuno-oncology. In particular, Nobel Prize winners James Allison of MD Anderson Cancer Center in Houston, Texas, and Tasuku Honjo of Kyoto University in Japan lifted the field of immunotherapy to international recognition for those outside …

Webinar - Tissue-based profiling for confident decisions in immuno-oncology

This live webcast will highlight benefits of standardizing tissue profiling for decision making in drug development and trial designs in immuno-oncology. Key topics include: Challenges in comparing results across different clinical studies that result from inconsistent biomarker strategies are discu…
Show more

Definiens Frequently Asked Questions

  • When was Definiens founded?

    Definiens was founded in 1994.

  • Who are Definiens key executives?

    Definiens's key executives are Thomas P. Heydler and Markus Schunk.

  • Who are Definiens competitors?

    Competitors of Definiens include Source Bioscience, Qiagen and Assertio Therapeutics.

  • Where is Definiens headquarters?

    Definiens headquarters is located at Bernhard-Wicki-Strasse 5, München.

  • Where are Definiens offices?

    Definiens has offices in München and Cambridge.

  • How many offices does Definiens have?

    Definiens has 2 offices.